Lady A’s Charles Kelley Shares Multiple Myeloma Diagnosis

When Lady A co-lead vocalist Charles Kelley revealed he has multiple myeloma, many fans were surprised by more than just the diagnosis itself. At 45, Kelley is a few decades younger than the average person diagnosed with the rare blood cancer.

View this post on Instagram

A post shared by Cassie Kelley (@cassiemkelley)

Kelley shared in a video posted to social media that doctors discovered the disease after investigating several unexplained rib fractures. Despite the diagnosis, he said he remains optimistic, noting that treatment options have improved dramatically in recent years.

His experience is also drawing attention to multiple myeloma, a cancer that, while relatively uncommon, affects thousands of Americans each year and can sometimes be difficult to recognize in its early stages.

What Is Multiple Myeloma?

Multiple myeloma is a cancer that forms in plasma cells, a type of white blood cell found in the bone marrow. These cells normally help the body fight infection by producing antibodies. In myeloma, abnormal plasma cells multiply and crowd out healthy blood-forming cells.

"Multiple myeloma occurs when plasma cells grow uncontrollably in the bone marrow," said Rachid Baz, MD, a hematologist in Moffitt Cancer Center’s Malignant Hematology Department and co-leader of the Pentecost Multiple Myeloma Research Center. "As those abnormal cells build up, they can weaken bones, affect blood cell production and increase the risk of complications throughout the body."

Symptoms can include bone pain, fatigue, anemia, recurrent infections and fractures. In some cases, the disease is discovered after routine blood work or testing ordered for another medical concern.

For Kelley, the diagnosis came after doctors investigated fractures that appeared without a clear cause.

Why Age Matters

Multiple myeloma is most often diagnosed later in life, with the average age at diagnosis around 69. While the disease can occur in younger adults, cases in people in their 40s are less common.

"Younger patients often have different considerations than older adults because they're balancing careers, family responsibilities and active lifestyles while undergoing treatment," Baz said. "At the same time, they may be able to tolerate more intensive therapies that can help control the disease while curative intent therapies are being developed and investigated."

Kelley alluded to that reality in his announcement, saying he plans to continue performing and working during treatment whenever possible.

Treatment Advances Offer Hope

While multiple myeloma is generally considered a chronic, treatable cancer, advances in targeted therapies, immunotherapy and stem cell transplantation have transformed care over the past two decades.

We've seen remarkable progress in the treatment of multiple myeloma. Many patients are living longer and maintaining a high quality of life thanks to therapies that simply weren't available a generation ago.

Rachid Baz, MD

"We've seen remarkable progress in the treatment of multiple myeloma," said Baz. "Many patients are living longer and maintaining a high quality of life thanks to therapies that simply weren't available a generation ago."

Newer approaches, including CAR T-cell therapy and other cellular immunotherapies, are also changing the treatment landscape for some patients with multiple myeloma. These therapies harness the body's own immune system to identify and attack cancer cells and have shown promising results, particularly for patients whose disease has returned after prior treatments.

At the same time, members of Moffitt’s Pentecost Family Myeloma Research Center are working to make treatment more personalized. Programs such as Moffitt's EMMA (Ex Vivo Mathematical Myeloma Advisor) platform are helping physicians better understand how an individual patient's myeloma cells may respond to different therapies, supporting more tailored treatment decisions.

"Multiple myeloma is not a one-size-fits-all disease," Baz said. "One of the most exciting areas of research is our ability to better understand each patient's disease and tailor treatment accordingly. Through clinical trials, cellular therapies and precision medicine approaches, we're continuing to move the field forward."

As Kelley begins treatment, his message has remained focused on hope, family and taking life one day at a time. His diagnosis serves as a reminder that although multiple myeloma remains incurable, ongoing advances in treatment are continuing to change what living with the disease looks like for many patients.